Matthew M Heeney

List of Publications by Year
in descending order

95 papers	4,476 citations	109321 35 h-index	106344 65 g-index
119 all docs	119 docs citations	119 times ranked	6557 citing authors

#	Article	IF	Citations
1	Mutations in TMPRSS6 cause iron-refractory iron deficiency anemia (IRIDA). Nature Genetics, 2008, 40, 569-571.	21.4	586
2	Common Variants at 10 Genomic Loci Influence Hemoglobin A1C Levels via Glycemic and Nonglycemic Pathways. Diabetes, 2010, 59, 3229-3239.	0.6	387
3	Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemiaâ€"TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. Lancet, The, 2016, 387, 661-670.	13.7	375
4	Definitions of the phenotypic manifestations of sickle cell disease. American Journal of Hematology, 2010, 85, 6-13.	4.1	291
5	Post-Transcriptional Genetic Silencing ofBCL11Ato Treat Sickle Cell Disease. New England Journal of Medicine, 2021, 384, 205-215.	27.0	250
6	Mutations in TRNT1 cause congenital sideroblastic anemia with immunodeficiency, fevers, and developmental delay (SIFD). Blood, 2014, 124, 2867-2871.	1.4	162
7	Lineage-specific BCL11A knockdown circumvents toxicities and reverses sickle phenotype. Journal of Clinical Investigation, 2016, 126, 3868-3878.	8.2	129
8	A Multinational Trial of Prasugrel for Sickle Cell Vaso-Occlusive Events. New England Journal of Medicine, 2016, 374, 625-635.	27.0	117
9	A novel syndrome of congenital sideroblastic anemia, B-cell immunodeficiency, periodic fevers, and developmental delay (SIFD). Blood, 2013, 122, 112-123.	1.4	101
10	Hydroxyurea for the treatment of sickle cell disease: Efficacy, barriers, toxicity, and management in children. Pediatric Blood and Cancer, 2012, 59, 365-371.	1.5	94
11	Congenital sideroblastic anemia due to mutations in the mitochondrial HSP70 homologue HSPA9. Blood, 2015, 126, 2734-2738.	1.4	78
12	Magnetic resonance imaging/angiography and transcranial Doppler velocities in sickle cell anemia: results from the SWiTCH trial. Blood, 2014, 124, 891-898.	1.4	75
13	Pial synangiosis in patients with moyamoya syndrome and sickle cell anemia: perioperative management and surgical outcome. Neurosurgical Focus, 2009, 26, E10.	2.3	74
14	Bacteremia Risk and Outpatient Management of Febrile Patients With Sickle Cell Disease. Pediatrics, 2013, 131, 1035-1041.	2.1	70
15	Iron-Refractory Iron Deficiency Anemia (IRIDA). Hematology/Oncology Clinics of North America, 2014, 28, 637-652.	2.2	68
16	Longâ€term safety and efficacy of deferasirox (Exjade^{Â®}) for up to 5â€ƒyears in transfusional ironâ€overloaded patients with sickle cell disease. British Journal of Haematology, 2011, 154, 387-397.	2.5	67
17	Successful hematopoietic stem cell mobilization and apheresis collection using plerixafor alone in sickle cell patients. Blood Advances, 2018, 2, 2505-2512.	5.2	62
18	Hydroxyurea for Children with Sickle Cell Disease. Pediatric Clinics of North America, 2008, 55, 483-501.	1.8	59

#	Article	IF	Citations
19	Hydroxyurea for Children with Sickle Cell Disease. Hematology/Oncology Clinics of North America, 2010, 24, 199-214.	2.2	58
20	Corticosteroids for acute chest syndrome in children with sickle cell disease: Variation in use and association with length of stay and readmission. American Journal of Hematology, 2010, 85, 24-28.	4.1	53
21	Transition from pediatric to adult care for sickle cell disease: Results of a survey of pediatric providers. American Journal of Hematology, 2011, 86, 512-515.	4.1	52
22	Thirtyâ€day readmission rates following hospitalization for pediatric sickle cell crisis at freestanding children's hospitals: Risk factors and hospital variation. Pediatric Blood and Cancer, 2012, 58, 61-65.	1.5	47
23	Platelet Activation and Inhibition iN Sickle cell disease (PAINS) study. Platelets, 2014, 25, 27-35.	2.3	47
24	Labelâ€Free Sickle Cell Disease Diagnosis using a Lowâ€Cost, Handheld Platform. Advanced Materials Technologies, 2016, 1, 1600100.	5.8	47
25	The effect of iron chelation therapy on overall survival in sickle cell disease and Î²â€thalassemia: A systematic review. American Journal of Hematology, 2018, 93, 943-952.	4.1	47
26	Hemoglobin SE diseaseâ€”A concise review. American Journal of Hematology, 2007, 82, 643-649.	4.1	46
27	Iron homeostasis and inherited iron overload disorders: an overview. Hematology/Oncology Clinics of North America, 2004, 18, 1379-1403.	2.2	44
28	UGT1A promoter polymorphisms influence bilirubin response to hydroxyurea therapy in sickle cell anemia. Translational Research, 2003, 141, 279-282.	2.3	42
29	Childhood autoimmune cytopenia secondary to unsuspected common variable immunodeficiency. Journal of Pediatrics, 2003, 143, 662-665.	1.8	40
30	Weight Status of Children With Sickle Cell Disease. Pediatrics, 2013, 131, e1168-e1173.	2.1	40
31	Newborn Screening for Sickle Cell Disease in Liberia: A Pilot Study. Pediatric Blood and Cancer, 2016, 63, 671-676.	1.5	40
32	Xâ€linked sideroblastic anemia due to ALAS2 intron 1 enhancer element GATAâ€binding site mutations. American Journal of Hematology, 2014, 89, 315-319.	4.1	39
33	Hematologic outcomes after total splenectomy and partial splenectomy for congenital hemolytic anemia. Journal of Pediatric Surgery, 2016, 51, 122-127.	1.6	39
34	Chronic transfusion practice for children with sickle cell anaemia and stroke. British Journal of Haematology, 2009, 145, 524-528.	2.5	38
35	Randomized phase 2 trial of regadenoson for treatment of acute vaso-occlusive crises in sickle cell disease. Blood Advances, 2017, 1, 1645-1649.	5.2	38
36	Chemical and Functional Analysis of Hydroxyurea Oral Solutions. Journal of Pediatric Hematology/Oncology, 2004, 26, 179-184.	0.6	37

#	Article	IF	Citations
37	Belzutifan, a Potent HIF2Î± Inhibitor, in the Pacakâ€“Zhuang Syndrome. New England Journal of Medicine, 2021, 385, 2059-2065.	27.0	36
38	Clinical practice guideline improves the treatment of sickle cell disease vasoocclusive pain. Pediatric Blood and Cancer, 2009, 52, 369-372.	1.5	34
39	Clinical outcomes of splenectomy in children: Report of the splenectomy in congenital hemolytic anemia registry. American Journal of Hematology, 2015, 90, 187-192.	4.1	33
40	A recurring mutation in the respiratory complex 1 protein NDUFB11 is responsible for a novel form of X-linked sideroblastic anemia. Blood, 2016, 128, 1913-1917.	1.4	33
41	Acquired immune cytopenias post-cardiac transplantation respond to rituximab. Pediatric Blood and Cancer, 2007, 48, 339-344.	1.5	32
42	Preventing Stroke Among Children With Sickle Cell Anemia: An Analysis of Strategies That Involve Transcranial Doppler Testing and Chronic Transfusion. Pediatrics, 2007, 120, e1107-e1116.	2.1	30
43	Double-blind, randomized, multicenter phase 2 study of SC411 in children with sickle cell disease (SCOT trial). Blood Advances, 2018, 2, 1969-1979.	5.2	29
44	High-Throughput Matrix-Assisted Laser Desorption Ionization-Time-of-Flight Mass Spectrometry Method for Quantification of Hepcidin in Human Urine. Analytical Chemistry, 2010, 82, 1551-1555.	6.5	28
45	Loss-of-function and gain-of-function phenotypes of stomatocytosis mutant RhAG F65S. American Journal of Physiology - Cell Physiology, 2011, 301, C1325-C1343.	4.6	24
46	Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: baseline results from the TWiTCH trial. American Journal of Hematology, 2015, 90, 806-810.	4.1	21
47	Prasugrel in Children With Sickle Cell Disease. Journal of Pediatric Hematology/Oncology, 2015, 37, 1-9.	0.6	21
48	TCD with Transfusions Changing to Hydroxyurea (TWiTCH): Hydroxyurea Therapy As an Alternative to Transfusions for Primary Stroke Prevention in Children with Sickle Cell Anemia. Blood, 2015, 126, 3-3.	1.4	19
49	Systemic Corticosteroids in Acute Chest Syndrome: Friend or Foe?. Paediatric Respiratory Reviews, 2014, 15, 24-27.	1.8	17
50	Normalizing hepcidin predicts TMPRSS6 mutation status in patients with chronic iron deficiency. Blood, 2018, 132, 448-452.	1.4	16
51	Encephalopathy From Lead Poisoning Masquerading as a Flu-Like Syndrome in an Autistic Child. Pediatric Emergency Care, 2010, 26, 370-373.	0.9	15
52	Flipping the Switch: Initial Results of Genetic Targeting of the Fetal to Adult Globin Switch in Sickle Cell Patients. Blood, 2018, 132, 1023-1023.	1.4	15
53	Real-time dose adjustment using point-of-care platelet reactivity testing in a double-blind study of prasugrel in children with sickle cell anaemia. Thrombosis and Haemostasis, 2017, 117, 580-588.	3.4	14
54	Design of the DOVE (Determining Effects of Platelet Inhibition on Vasoâ€Occlusive Events) trial: A global Phase 3 doubleâ€blind, randomized, placeboâ€controlled, multicenter study of the efficacy and safety of prasugrel in pediatric patients with sickle cell anemia utilizing a dose titration strategy. Pediatric Blood and Cancer, 2016, 63, 299-305.	1.5	13

#	Article	IF	Citations
55	Mutations in the iron-sulfur cluster biogenesis protein HSCB cause congenital sideroblastic anemia. Journal of Clinical Investigation, 2020, 130, 5245-5256.	8.2	13
56	Increased expression of anti-apoptosis genes in peripheral blood cells from patients with paroxysmal nocturnal hemoglobinuria. Molecular Genetics and Metabolism, 2003, 78, 291-294.	1.1	12
57	Biochemical and therapeutic effects of Omega-3 fatty acids in sickle cell disease. Complementary Therapies in Medicine, 2020, 52, 102482.	2.7	12
58	Hydroxyurea Optimization through Precision Study (HOPS): study protocol for a randomized, multicenter trial in children with sickle cell anemia. Trials, 2020, 21, 983.	1.6	11
59	SLC25A38 congenital sideroblastic anemia: Phenotypes and genotypes of 31 individuals from 24 families, including 11 novel mutations, and a review of the literature. Human Mutation, 2021, 42, 1367-1383.	2.5	11
60	Hemoglobinopathies mimicking Hb S/Î²-thalassemia: Hb S/S with Î±-thalassemia and Hb S/Volga. American Journal of Hematology, 2006, 81, 361-365.	4.1	10
61	Deferasirox (ExjadeÂ®), the Once-Daily Oral Iron Chelator, Demonstrates Safety and Efficacy in Patients with Sickle Cell Disease (SCD): 3.5-Year Follow-up.. Blood, 2008, 112, 1420-1420.	1.4	10
62	Cefepimeâ€induced neutropenia in a teenager. Pediatric Blood and Cancer, 2008, 51, 715-716.	1.5	8
63	Successful utilization of an electronic pain diary in a multinational phase 3 interventional study of pediatric sickle cell anemia. Clinical Trials, 2017, 14, 563-571.	1.6	8
64	Neonatal anemia: Revisiting the enigmatic pyknocyte. American Journal of Hematology, 2017, 92, 717-721.	4.1	7
65	Clinical Outcomes For Patients With Sickle Cell Disease: 24-Month Follow-Up In An Ongoing 3-Year, Prospective, Non-Interventional Registry Trial. Blood, 2013, 122, 988-988.	1.4	7
66	Sickle cell disease caused by Hb S/QuÃ©bec-CHORI: Treatment with hydroxyurea and response. Pediatric Blood and Cancer, 2007, 49, 207-210.	1.5	6
67	Ticagrelor versus placebo for the reduction of vaso-occlusive crises in pediatric sickle cell disease: Rationale and design of a randomized, double-blind, parallel-group, multicenter phase 3 study (HESTIA3). Contemporary Clinical Trials, 2019, 85, 105835.	1.8	6
68	A systematic review of ketamine for the management of vasoâ€occlusive pain in sickle cell disease. Pediatric Blood and Cancer, 2021, 68, e28989.	1.5	6
69	Interpretation of Fetal Hemoglobin Only on Newborn Screening for Hemoglobinopathy. Journal of Pediatric Hematology/Oncology, 2002, 24, 499-502.	0.6	5
70	Iron clad: iron homeostasis and the diagnosis of hereditary iron overload. Hematology American Society of Hematology Education Program, 2014, 2014, 202-209.	2.5	5
71	Longâ€term hematologic and clinical outcomes of splenectomy in children with hereditary spherocytosis and sickle cell disease. Pediatric Blood and Cancer, 2020, 67, e28290.	1.5	5
72	Long-Term Efficacy and Safety of Deferasirox (ExjadeÂ®, ICL670), a Once-Daily Oral Iron Chelator, in Patients with Sickle Cell Disease (SCD).. Blood, 2007, 110, 3395-3395.	1.4	5

#	Article	IF	Citations
73	Ticagrelor versus placebo for the reduction of vaso-occlusive crises in pediatric sickle cell disease: the HESTIA3 study. Blood, 0, , .	1.4	5
74	Ringed sideroblasts in Î²â€thalassemia. Pediatric Blood and Cancer, 2017, 64, e26324.	1.5	4
75	Alu element insertion inPKLRgene as a novel cause of pyruvate kinase deficiency in Middle Eastern patients. Human Mutation, 2018, 39, 389-393.	2.5	4
76	Clinical and laboratory outcomes following total or partial splenectomy in patients with hereditary spherocytosis. Pediatric Hematology and Oncology, 2019, 36, 382-389.	0.8	4
77	The Clinical and Genetic Spectrum of TMPRSS6 Mutations Leading to Inappropriate Hepcidin Expression and Iron Refractory Iron Deficiency Anemia (IRIDA).. Blood, 2009, 114, 629-629.	1.4	4
78	Baseline Characteristics of Patients with Sickle Cell Disease in An Ongoing 5-Year, Prospective, Noninterventional Registry Trial. Blood, 2011, 118, 1060-1060.	1.4	4
79	Variation in Serial TCD Velocity Measurements in the TCD with Transfusions Changing to Hydroxyurea (TWiTCH) Trial. Blood, 2016, 128, 1019-1019.	1.4	4
80	Resolution of cerebral artery stenosis in a child with sickle cell anemia treated with hydroxyurea. American Journal of Hematology, 2010, 85, 135-137.	4.1	3
81	Clinical and Pathophysiological Aspects of Sickle Cell Anemia. , 2009, , 437-496.		3
82	Bronchodilator Use for Acute Chest Syndrome Among Large Pediatric Hospitals in North America. Clinical Pediatrics, 2018, 57, 1630-1637.	0.8	3
83	Changes in Extrahepatic Iron Load in Response to Iron Chelation Versus Phlebotomy: Observations from the Twitch Trial. Blood, 2016, 128, 202-202.	1.4	3
84	A Scientific Renaissance. Pediatric Clinics of North America, 2018, 65, 445-464.	1.8	1
85	A Multistep Model for the Pathogenesis and Evolution of PNH. , 2003, , 41-53.		1
86	Long-Term Safety and Efficacy of Deferasirox (ExjadeÂ®) In Transfused Patients with Sickle Cell Disease Treated for up to 5 Years. Blood, 2010, 116, 845-845.	1.4	1
87	Comparison of Clinical Outcomes Between Adult and Pediatric Patients (pts) with Sickle Cell Disease (SCD): 3-Year (y) Follow-up in a Prospective, Longitudinal, Noninterventional Registry Trial. Blood, 2014, 124, 4890-4890.	1.4	1
88	Standardizing Opioid Prescribing in a Pediatric Hospital: A Quality Improvement Effort. Hospital Pediatrics, 2022, 12, 164-173.	1.3	1
89	Iron Disorders. Hematology/Oncology Clinics of North America, 2014, 28, ix-x.	2.2	0
90	Disease Diagnostics: Labelâ€Free Sickle Cell Disease Diagnosis using a Lowâ€Cost, Handheld Platform (Adv.) Tj ETQq0 0 0 rgBT /Overloc	5.8	0

#	Article	IF	Citations
91	Platelet Activation and Inhibition in Sickle Cell Disease (PAINS) Study. Blood, 2012, 120, 5147-5147.	1.4	0
92	12-Month Follow-up for Patients with Sickle Cell Disease in an Ongoing 3-Year, Prospective, Non-Interventional Registry Trial. Blood, 2012, 120, 1010-1010.	1.4	0
93	Prasugrel in Children with Sickle Cell Disease: Pharmacokinetic and Pharmacodynamic Characteristics from an Open-Label, Adaptive-Design, Dose-Ranging Study. Blood, 2012, 120, 3213-3213.	1.4	0
94	Optimized Beta-Globin Expression and Enucleation from Induced Red Blood Cells for In Vitro Modeling of Sickle Cell Disease. Blood, 2018, 132, 2359-2359.	1.4	0
95	Study Design and Initial Baseline Characteristics in Solace-Kids: Crizanlizumab in Pediatric Patients with Sickle Cell Disease. Blood, 2020, 136, 22-24.	1.4	0